FOSUN PHARMA's Venlafaxine Hydrochloride Extended-Release Tablets Receive Market Approval

Stock News05-08

FOSUN PHARMA (02196) has announced that its controlled subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Venlafaxine Hydrochloride Extended-Release Tablets. The approved indications are for the treatment of depression, including depression accompanied by anxiety, and generalized anxiety disorder. The drug is a chemically synthesized pharmaceutical independently developed by the group. As of April 2026, the cumulative R&D investment for this drug by the group amounted to approximately RMB 7.68 million (unaudited). The market approval of this product is expected to further diversify the group's portfolio of related pharmaceutical formulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105978375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105978375","market":"sg","top_or_hot":-1,"title":"FOSUN PHARMA's Venlafaxine Hydrochloride Extended-Release Tablets Receive Market Approval","media":"Stock News","content":"<p>FOSUN PHARMA (02196) has announced that its controlled subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Venlafaxine Hydrochloride Extended-Release Tablets. The approved indications are for the treatment of depression, including depression accompanied by anxiety, and generalized anxiety disorder. The drug is a chemically synthesized pharmaceutical independently developed by the group. As of April 2026, the cumulative R&D investment for this drug by the group amounted to approximately RMB 7.68 million (unaudited). The market approval of this product is expected to further diversify the group's portfolio of related pharmaceutical formulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA's Venlafaxine Hydrochloride Extended-Release Tablets Receive Market Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA's Venlafaxine Hydrochloride Extended-Release Tablets Receive Market Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-08 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) has announced that its controlled subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Venlafaxine Hydrochloride Extended-Release Tablets. The approved indications are for the treatment of depression, including depression accompanied by anxiety, and generalized anxiety disorder. The drug is a chemically synthesized pharmaceutical independently developed by the group. As of April 2026, the cumulative R&D investment for this drug by the group amounted to approximately RMB 7.68 million (unaudited). The market approval of this product is expected to further diversify the group's portfolio of related pharmaceutical formulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"","article_id":"1105978375","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105978375","pubTimestamp":1778231677,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) has announced that its controlled subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., recently received approval from the National Medical Products Administration for the drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0175":"白马股","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK1593":"医美概念股","02196":"复星医药","BK1515":"抗疫概念","BK0028":"国家队","BK1191":"制药","BK0239":"医药制造","BK0188":"融资融券","BK0183":"MSCI概念","IPOS":"Renaissance International IPO ETF","BK0096":"民营医院","BK0012":"证金概念"},"translate_title":"复星医药盐酸文拉法辛缓释片获上市批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1,"IPOS":1},"content_text":"FOSUN PHARMA (02196) has announced that its controlled subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Venlafaxine Hydrochloride Extended-Release Tablets. The approved indications are for the treatment of depression, including depression accompanied by anxiety, and generalized anxiety disorder. The drug is a chemically synthesized pharmaceutical independently developed by the group. As of April 2026, the cumulative R&D investment for this drug by the group amounted to approximately RMB 7.68 million (unaudited). The market approval of this product is expected to further diversify the group's portfolio of related pharmaceutical formulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105978375","isCrawlerRequest":true}